Rheumatoid arthritis (RA) is a complex genetic disease where numerous genetic factors contribute to susceptibility. 1 The genes most thoroughly studied with regard to predisposition to RA are within the HLA-DR loci, 2 but HLA-DR accounts for only about one-third of the genetic predisposition to RA. Attractive candidates for additional susceptibility or progression factors are cytokine genes. Cytokines are important mediators of the immune and inflammatory response and play an important role in the pathophysiology of joint inflammation and destruction in RA. 3, 4 Significant amounts of pro-and anti-inflammatory cytokines are found in joints affected by RA. The inability of the anti-inflammatory mechanisms to downregulate the inflammatory process of RA adequately has not been explained, but has been incorporated into the concept that RA is a consequence of cytokine disequilibrium. 4, 5 IL-6 was initially thought to be a pro-inflammatory cytokine involved in the pathogenesis of chronic inflammatory disorders like RA. 6, 7 However, other findings suggest that IL-6 may act as an anti-inflammatory mediator. 8, 9 IL-6 has been observed to augment circulating levels of IL-1 receptor antagonist and soluble tumour necrosis factor (TNF) receptor, both of which could have important anti-inflammatory effects by suppressing the action of IL-1 and TNF. 10 Cytokine expression has been shown to be modulated by polymorphisms within the promoter regions of the genes. 11, 12 Along this line, the regulation of IL-6 may be in part genetically determined by polymorphisms within its promoter region. Several polymorphisms have been described in the IL-6 gene, including two single nucleotide polymorphisms (SNP) located at positions −622 and −174 in the 5Ј flanking region. 13, 14 The −174 polymorphism consists of a G to C substitution, which has been shown to affect IL-6 levels and is associated with systemic juvenile chronic arthritis (S-JCA). 14 We therefore undertook the present study to investigate whether the recently described IL-6 promoter polymorphisms were associated with susceptibility to and/or outcome of RA. We used a PCR-RFLP method for typing the −622 and −174 IL-6 promoter polymorphisms ( Figure 1 ). We typed 163 RA patients and 157 control subjects.
Complete linkage disequilibrium was observed between the −622 and −174 alleles (Table 1 ). All the samples homozygous for allele G at −622 were homozygous for allele G at −174, and all the samples homozygous for allele A at −622 were homozygous for C at −174; furthermore, heterozygote samples at position −622 were invariably heterozygous at −174. Therefore, −622 and −174 genotypes and alleles occurred at identical frequencies.
The distribution of IL-6 promoter genotype and allele frequencies in RA patients and control subjects is shown in Table 1 . No difference was observed for IL-6 promoter genotype or allele distribution between patients and controls. In the control population the genotype and allele frequencies show little or no differences from the previously reported distribution among Western European Caucasians and were different from other racial groups.
14 This is consistent with previous data showing considerable inter-ethnic variation in the frequencies of other IL-6 polymorphisms. 15 This is the first report describing the association between IL-6 promoter polymorphisms and RA. We found no evidence for genetic association conferred by these polymorphisms with respect to susceptibility to RA. MspI and BglII RFLPs within the human IL-6 locus have been analysed with respect to susceptibility to RA A 525-bp fragment containing both polymorphic sites (−622 and −174) was amplified using the following primers (both shown 5Ј-3Ј): GGAGTCACACACTCCACCT (forward) and CTGATTGGAAACC TTATTAAG (reverse). Samples were subjected to a denaturation step at 94°C for 5 min followed by 30 cycles in a PCR Gene Amp System 2400 thermocycler (Perkin-Elmer/Cetus). Each cycle was as follows: 94°C for 54 sec, 57°C for 30 sec and 72°C for 10 sec; the last cycle was followed by a 10-min incubation at 72°C. A 15 laliquot of the PCR-product was digested at 37°C for 2 h with either FokI and Hsp92II (New England Biolabs and Promega respectively). Allele sizes were confirmed in selected DNA samples, using an ABI DNA sequencer (data not shown). (a) Examples of patterns observed after Hsp92II digestion for each −174 genotype; lanes 1, 2 and 3 correspond to individuals GG, CC and GC respectively. (b) Examples of patterns observed after FokI digestion for each −622 genotype; lanes 4, 5 and 6 correspond to individuals GG, AA and GA respectively. 28 at Servicio de Reumatología, Hospital Universitario Virgen de las Nieves, Granada. The clinical and laboratory characteristics of the patients were as follows: 83.3% of the patients were female and age at onset was 50.7 ± 14 years; the mean disease duration was 9.1 ± 5 years and 78.5% were rheumatoid factor positive. Twenty-six percent of the patients presented nodular disease, 9.6% presented additional extra-articular disease and disease-related surgery was performed in 10.7% of the patients. All parameters were checked for evidence at any time during disease evolution. Data analysis were performed by the 2 method with Yates correction or Fisher's exact test if appropriate. The mean age at onset and mean disease duration were compared by the t-test. The Hardy-Weinberg equilibrium was tested by Goodness of Fit test using gene frequencies of the healthy individuals.
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and, consistent with our data, no association was observed. 16, 17 Other authors have described an association of 3Ј flanking region IL-6 polymorphisms with peak bone mass 18 and more recently, SLE patients have been shown to demonstrate greater variability in the IL-6 3Ј polymorphic region than healthy controls, 19 with SLEassociated alleles contributing to altered IL-6 expression. 20 A novel SNP located at position −573 has been recently described in African-Americans. 21 To our knowledge, neither the −573 SNP or the 3Ј minisatellites have been analysed in RA.
Cytokine promoter polymorphisms have been associated not only with susceptibility but also with outcome in human athritides. We therefore examined the IL-6 genotypes of the RA patients with regard to clinical and laboratory parameters. No significant differences were observed when we analysed IL-6 genotypes according to sex, presence of rheumatoid factor, extra-articular manifestations or mean disease duration. Interestingly, we did find significant differences in the mean age at disease onset between patients homozygous at −174 CC (43.2 ± 16 years) and those homozygous at −174 GG (51.25 ± 12 years) (P = 0.03). The mean age for heterozygous −174 CG was intermediate between the mean for homozygotes (48.8 ± 13 years). Allele −174 C is associated with a reduced IL-6 promoter strength in reporter gene expression experiments, and that IL-6 serum levels are lower in subjects with the CC genotype compared with GC or GG subjects.
14 Consequently, it is possible that a reduced ability to express IL-6 would favour an earlier disease onset, which would be consistent with an antiinflammatory effect of this cytokine.
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Our results are in apparent contrast with those obtained by Fishman et al 14 in S-JCA who found a significant reduction in CC genotype frequency in S-JCA patients with age of onset at р5 years. However, RA and S-JCA are distinct entities that can differ in the inductive and/or effector phases of their pathogenesis and a different role of IL-6 in these disease cannot be discarded. Along this line, it has been shown that IL-6 can have a varying relevance in different experimental models of arthritis. Thus, ablation of IL-6 production by gene targeting disruption interferes with the development of both collagen-induced 22 and antigen-induced 23 arthritis in mice, while arthritis in IL-6 −/− TNF␣ transgenic mice is unaffected. 22 Contradictory effects of IL-6 have also been reported in knockout models of this cytokine when examining the response to different inflammatory stimuli. While an overall normal inflammatory response, paralleled with three-fold higher TNF␣ levels, 24 resulted in IL-6 −/− mice after a systemic stimulus (LPS), an impaired response in these mice was observed when a local stimulus (turpentine) was used. 24, 25 This is consistent with in vitro and in vivo evidence supporting the concept that the IL-6 system plays a sensitive role in local inflammatory reactions by amplifying leukocyte recruitment 26 and with the capacity of IL-6 to protect against LPS toxicity.
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In summary, the data from the present study indicate that the IL-6 promoter polymorphisms studied do not play a major role as genetic susceptibility factors for RA. However, IL-6 genotypes may contribute to the pathogenesis to the disease by influencing the age at disease onset.
